Lewes, DE -- (SBWIRE) -- 11/18/2015 -- Report forecast the pompe disease market in the US to grow at a CAGR of 10.68% over the period 2014-2019.

Pompe disease, a type of LSD, is caused by mutations in the GAA gene. These mutations inhibit the mechanism of action of GAA, an enzyme responsible for catabolizing glycogen, resulting in accumulation of glycogen in the lysosomes of the cells. The buildup of glycogen in certain organs and tissues, especially in the muscles, hinders the normal functions of the organs. Pompe disease can be further classified as infantile-onset and adult-onset Pompe disease. As the disease is an autosomal recessive hereditary disorder, both parents are carriers and can pass one copy of the mutated gene to their offspring. The disease affects both men and women.

This report covers the present scenario and the growth prospects of the pompe disease market in US for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of the drugs available in the US market and the drug candidates that are in various phases of development for the treatment of Pompe disease.

The report also presents the vendor landscape and a corresponding detailed analysis of the major vendors in the market. In addition, it discusses the major drivers that influence the growth and the challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.

Pompe Disease Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It also covers the landscape of the market in the US and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

According to the report, the special provision for orphan drugs given by the FDA in terms of market exclusivity and tax benefits for a specified time, is one factor. Also, the presence of high unmet needs for appropriate drugs is another major factor propelling the growth of the market.

Key players in the Pompe Disease Market in US: Amicus Therapeutics, BioMarin Pharmaceutical and Genzyme

Other Prominent Vendors in the market are: Audentes Therapeutics, EpiVax, Oxyrane, Sangamo BioSciences, and Valerion Therapeutics.

Market driver
- Special provision for orphan drugs
- For a full, detailed list, view our report

Market challenge
- Limited patient population
- For a full, detailed list, view our report

Market trend
- Growing public awareness
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Spanning over 56 pages "Pompe Disease Market in the US 2015-2019" report covers Executive summary, Scope of the report, Market research methodology, Introduction, Market landscape, Disease overview, Orphan drug in the US, Pipeline analysis, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Key vendor analysis, Appendix.

Find more information Visit at: http://www.marketresearchreports.com/technavio/pompe-disease-market-us-2015-2019

Find all Treatments report at: http://www.marketresearchreports.com/treatments

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions